ReviewMinerva endocrinologica2013
Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.
Review in Minerva endocrinologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 53 citations in OpenAlex.
- Trial
- Evaluation of Intradermal and Subcutaneous Infusion Set Performance Under 24-Hour Basal and Bolus Conditions.Journal of diabetes science and technology · 2015Trial
- Microfluidic-engineered glucose-responsive microparticle depot for smart insulin delivery.Drug delivery · 2026Article
- Exploring the Potential of Nuciferine in Diabetes ManagementCurrent medicinal chemistry · 2026Article
- Observational
- Adipose stromal cells increase insulin sensitivity and decrease liver gluconeogenesis in a mouse model of type 1 diabetes mellitus.Stem cell research & therapy · 2025Article
- What Really Matters?: How Insulin Dose, Timing, and Distribution Relate to Meal Composition in Free-Living People with Type 1 Diabetes.Diabetes technology & therapeutics · 2025Article
- The Role of Selenium Nanoparticles in Addressing Diabetic Complications: A Comprehensive Study.Current topics in medicinal chemistry · 2024Review
- Nanotheranostics: application of nanosensors in diabetes management.Journal of diabetes and metabolic disorders · 2023Review
- Insulin pumps in children - a systematic review.World journal of clinical pediatrics · 2022Article
- Tolerogenic Delivery of a Hybrid Insulin Peptide Markedly Prolongs Islet Graft Survival in the NOD Mouse.Diabetes · 2022Article
- Exosome-mediated improvement in membrane integrity and muscle function in dystrophic mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- The powerful world of antisense oligonucleotides: From bench to bedside.Wiley interdisciplinary reviews. RNA · 2020Review
- The Role of Self-regulation Failures and Self-care in the Link Between Daily Sleep Quality and Blood Glucose Among Adults with Type 1 Diabetes.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2020Article
- Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes.Endocrine reviews · 2019Review
- An Overview on Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases.Iranian journal of pharmaceutical research : IJPR · 2019Review
- Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security.Cost effectiveness and resource allocation : C/E · 2019Article
- Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.European journal of drug metabolism and pharmacokinetics · 2018Review
- Antidiabetic Potential of Monoterpenes: A Case of Small Molecules Punching above Their Weight.International journal of molecular sciences · 2017Review
- Design of the Glucose Rate Increase Detector: A Meal Detection Module for the Health Monitoring System.Journal of diabetes science and technology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Type 1 diabetes is a disorder where slow destruction of pancreatic β-cells occurs through autoimmune mechanisms. The result is a progressive and ultimately complete lack of endogenous insulin. Due to β-cell lack, secondary abnormalities in glucagon and likely in incretins occur. These multiple hormonal abnormalities cause metabolic instability and extreme glycemic variability, which is the primary phenotype. As the disease progresses patients often develop hypoglycemia unawareness and defects in their counterregulatory defenses. Intensive insulin therapy may thus lead to 3-fold excess of severe hypoglycemia and severely hinder the effective and safe control of hyperglycemia. The main goal of the therapy for type 1 diabetes has long been physiological mimicry of normal insulin secretion based on monitoring which requires considerable effort and understanding of the underlying physiology. Attainment of this goal is challenged by the nature of the disease and our current lack of means to fully repair the abnormal endocrine pancreas interactive functions. As a result, various insulin preparations have been developed to partially compensate for the inability to deliver timely exogenous insulin directly to the portal/intrapancreatic circulation. It remains an ongoing task to identify the ideal routes and regimens of their delivery and potentially that of other hormones to restore the deficient and disordered hormonal environment of the pancreas to achieve a near normal metabolic state. Several recent technological advances help addressing these goals, including the rapid progress in insulin pumps, continuous glucose sensors, and ultimately the artificial pancreas closed-loop technology and the recent start of dual-hormone therapies.
Indexed as
Identifiers
23732369PMC4220674W138744020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.